Key result
Elevated circulating ICAM-2 identifies idiopathic myocardial fibrosis in chimpanzees with 100% specificity.
Why the study?
Idiopathic myocardial fibrosis is prevalent and life-threatening in captive chimpanzees, but ante-mortem diagnosis is challenging due to limitations of current veterinary diagnostics.
Do circulating serum protein biomarkers (ICAM-2, AXL, PECAM-1) accurately detect idiopathic myocardial fibrosis in chimpanzees?
Observational (n=25)
Yes
Do circulating serum protein biomarkers (ICAM-2, AXL, PECAM-1) accurately detect idiopathic myocardial fibrosis in chimpanzees?
ICAM-2 was identified as a highly specific biomarker for detecting moderate-to-severe idiopathic myocardial fibrosis in chimpanzees.
Answers are grounded in this paper and cite their sources.
ICAM-2 may support noninvasive detection of myocardial fibrosis in chimpanzees; hypothesis-generating and leaves open validation plus translation to other species.
Background Idiopathic myocardial fibrosis (IMF) is a prevalent and life-threatening condition in captive chimpanzees ( Pan troglodytes ). Ante-mortem diagnosis remains challenging due to the limitations of current veterinary diagnostics. This study aimed to identify and validate circulating serum protein biomarkers for the detection of IMF. Methods Serum samples collected from zoo-housed chimpanzees with post-mortem confirmed cardiac phenotypes were utilized. An initial discovery phase using a Proximity Extension Assay (PEA) screened 92 cardiovascular proteins in a subset of 10 chimpanzees. Three candidate biomarkers (ICAM-2, AXL, and PECAM-1) were subsequently selected for Enzyme-Linked Immunosorbent Assay (ELISA) validation in a broader cohort ( N = 25). Final biomarker efficacy was assessed alongside Receiver Operating Characteristic (ROC) curve analysis. Results In the discovery phase, ICAM-2, AXL, and PECAM-1 were significantly elevated in IMF-affected animals. During ELISA validation, circulating ICAM-2 remained significantly elevated in the IMF cohort ( p = 0.010, Cohen’s d = 0.91). No significant association was detected with subject age or the time interval between sampling and death. AXL and PECAM-1 did not reach statistical significance in the validation cohort. ROC analysis for ICAM-2 established an optimal diagnostic cut-off of >1.535 ng/mL (AUC = 0.672), which demonstrated 100% specificity and a 100% positive predictive value. Conclusion ICAM-2 is a highly specific, putative “rule-in” biomarker for moderate-to-severe IMF in chimpanzees. Implementing this biomarker into routine health assessments could enhance the early, non-invasive detection and clinical management of cardiovascular disease in this endangered species, though further validation is required before wider clinical use.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2026) conducted an observational in Idiopathic myocardial fibrosis (IMF) (n=25). Elevated ICAM-2 biomarker levels vs. Healthy controls was evaluated on Circulating ICAM-2 concentration (Cohen's d = 0.91, p=0.010). Circulating ICAM-2 was significantly elevated in chimpanzees with idiopathic myocardial fibrosis compared to healthy controls (1.88 vs 0.52 ng/mL, p=0.010), demonstrating 100% specificity at a diagnostic cut-off of >1.535 ng/mL.
Synapse has enriched 10 related papers. Consider them for comparative context: